Viewing Study NCT04162756


Ignite Creation Date: 2025-12-24 @ 11:16 PM
Ignite Modification Date: 2026-01-10 @ 3:17 PM
Study NCT ID: NCT04162756
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2021-10-14
First Post: 2019-11-11
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Sponsor: Kite, A Gilead Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module